ATAI
$3.49-0.08 (-2.24%)
AtaiBeckley Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of mental health treatments in the United States, Germany, and Canada.
Recent News
Assessing AtaiBeckley (ATAI) Valuation As Strong Long Term Returns Contrast With Heavy Losses
Why AtaiBeckley (ATAI) is on investors’ radar today AtaiBeckley (ATAI) has attracted fresh attention after a period of mixed share performance, including a roughly 2% move lower over the past day and a negative trend over the past week. For readers tracking shorter term shifts, the stock shows a small move over the past month, a weaker patch over the past 3 months, and a significantly positive total return over the past year. See our latest analysis for AtaiBeckley. Short-term momentum has...
AtaiBeckley reports rapid, sustained antidepressant effects in Phase 2a study of BPL-003
AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC) has announced the publication of results from its ongoing Phase 2a clinical study of its investigational treatment for treatment-resistant depression (TRD), BPL-003, reporting rapid and sustained antidepressant effects in a small patient cohort. The...
AtaiBeckley outlines plans for Phase 3 trials of BPL-003 in treatment-resistant depression at Investor Day
AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC) highlighted progress across its clinical pipeline and reaffirmed its financial outlook during its 2026 Virtual Investor Day, outlining plans to advance its lead candidate BPL-003 into Phase 3 trials for treatment-resistant depression while continuing...
Sector Update: Health Care Stocks Higher Late Afternoon
Health care stocks were higher late Monday afternoon, with the NYSE Health Care Index up 0.7% and th
AtaiBeckley’s FDA Backing And Trial Data Reframe Mental Health Upside And Risk
AtaiBeckley received FDA support to advance BPL-003 into Phase 3 studies for treatment resistant depression. The company reported encouraging Phase 2a results for EMP-01 in social anxiety disorder. These developments add new data and regulatory momentum to AtaiBeckley’s mental health pipeline. AtaiBeckley, listed as NasdaqGM:ATAI, is drawing fresh attention after securing FDA backing for BPL-003 and sharing positive early data for EMP-01. The stock last closed at $3.39, with a 1 year return...